Product Description
LBL-019 from Leads Biolabs is a TNFR2 antagonist aiming at malignant tumors. It is a first-in-class drug targeting TNFR2 that has been approved for a clinical trial in China and has also been recently approved for a clinical trial by the Food and Drug Administration (FDA) according to its official website. (Sourced from: https://www.frontiersin.org/articles/10.3389/fimmu.2022.844931/pdf)
Mechanisms of Action: TNFR2 Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nanjing Leads Biolabs
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05223231 |
LBL-019-CN001 | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2025-10-22 |
12% |
2025-05-08 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/13/2024 |
News Article |
Leads Biolabs is Proud to Announce its Participation in the 2024 ASCO Annual Meeting with One Oral Presentation and Two Posters. |